

Haematologica
HAEMATOL/2019/244418
Version 3

Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma.

Keiichiro Watanabe, Ariunzaya Bat-Erdene, Hirofumi Tenshin, Qu Cui, Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Takeshi Harada, Hirokazu Miki, Kimiko Sogabe, Masahiro Oura, Ryohei Sumitani, Yukari Mitsui, Itsuro Endo, Eiji Tanaka, Makoto Kawatani, Hiroyuki Osada, Toshio Matsumoto, and Masahiro Abe

Disclosures: MA received research funding from Chugai Pharmaceutical, Sanofi KK, Pfizer Seiyaku KK, Kyowa Hakko Kirin, MSD KK, Astellas Pharma, Takeda Pharmaceutical, Teijin Pharma and Ono Pharmaceutical, and honoraria from Daiichi Sankyo Company. The other authors declare no competing financial interests.

Contributions: KW, AB, HT, MK, HO, and MA designed the research and conceived the project. Animal experiments were performed by KW, QC, HT, TH, HM, KS, MO, RS, and JT; cell cultures by KW, AB, HT, AO, TH, KS, MO, and RS; immunoblotting by AB, JT, HT, AO, and MH; and bone analyses by KW, QC, YM, MH, IE, and ET. KW, AB, HT, MK, HO, TM, and MA analyzed and discussed the data, and wrote the manuscript.